Related Experiment Video
Updated: Feb 27, 2026
07:39
Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
Published on: August 16, 2021
4.2K
Interatrial shunt devices for heart failure with normal ejection fraction: a technology update.
Joseph J Cuthbert1, Pierpaolo Pellicori1, Andrew L Clark1
1Department of Cardiology, Hull York Medical School, Hull and East Yorkshire Medical Research and Teaching Centre, Castle Hill Hospital, Cottingham, Kingston upon Hull, UK.
Medical Devices (Auckland, N.Z.)
|June 28, 2017
Summary
Heart failure with normal ejection fraction (HeFNEF) causes significant hospital admissions. This review explores therapeutic devices aimed at reducing left atrial pressure to alleviate exertional breathlessness in HeFNEF patients.
Area of Science:
- Cardiology
- Medical Devices
- Heart Failure Research
Background:
- Heart failure with normal ejection fraction (HeFNEF) represents approximately 50% of heart failure admissions.
- The underlying pathophysiology and clear diagnostic criteria for HeFNEF remain incompletely defined, impeding effective treatment development.
- Exertional breathlessness is a primary clinical symptom, often linked to elevated left atrial pressure during physical activity.
Purpose of the Study:
- To review potential therapeutic strategies for HeFNEF, focusing on interatrial communication.
- To discuss percutaneously delivered devices currently under investigation for managing HeFNEF.
Main Methods:
- Review of current research and investigational devices for HeFNEF.
- Focus on devices designed to create an interatrial communication.
- Discussion of percutaneous delivery methods for these devices.
Main Results:
- Identified two distinct percutaneously delivered devices as promising therapeutic options.
- These devices aim to alleviate left atrial pressure, a key factor in HeFNEF symptoms.
Conclusions:
- Interatrial communication is a viable therapeutic concept for HeFNEF.
- Percutaneous devices offer a minimally invasive approach to creating this communication.
- Further investigation into these devices is warranted for effective HeFNEF treatment.
Related Concept Videos
01:22Heart Failure VI: Adjunct Therapies
466
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
466
01:30Heart Failure V: Medical Management
419
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
419
01:29Cardiomyopathy V: Interprofessional Care
542
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
542
01:29Heart Failure II: Pathophysiology
1.1K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.1K
01:30Cardiomyopathy II: Dilated Cardiomyopathy
667
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
667
01:26Heart Failure Drugs: Inotropic Agents
1.7K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.7K